NCT06531941Phase 2Active not recruiting

Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism

Study sponsor: MBX Biosciences

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-05Estimated
Enrollment · participants60Actual
Source updated2026-10-07Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Primary completion date changed

Before: 27 May 2027. After: May 2028.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview